Skip to main content
. 2010 May 27;6(5):e1000921. doi: 10.1371/journal.ppat.1000921

Figure 6. CLDC+MPF enhanced survival of SchuS4 infection in vivo.

Figure 6

(A) Mice (n = 10 per group) were treated with CLDC+MPF i.v. 3 days prior to intranasal challenge with SchuS4. Significantly more CLDC+MPF treated mice survived infection compared to untreated controls (p = 0.0027). (B) Wild type (WT) or nos2/gp91−/−mice (n = 5 per group) were treated with CLDC+MPF 3 days prior to challenge with SchuS4. Sixty percent of CDLC+MPF treated WT mice survived infection, whereas significantly fewer nos2/gp91−/− survived (p = 0.0385). Data are representative of two experiments.